PBYI
Price
$3.28
Change
-$0.12 (-3.53%)
Updated
Jul 25 closing price
Capitalization
162.81M
11 days until earnings call
RGNX
Price
$8.96
Change
-$0.17 (-1.86%)
Updated
Jul 25 closing price
Capitalization
451.48M
3 days until earnings call
Interact to see
Advertisement

PBYI vs RGNX

Header iconPBYI vs RGNX Comparison
Open Charts PBYI vs RGNXBanner chart's image
Puma Biotechnology
Price$3.28
Change-$0.12 (-3.53%)
Volume$300.34K
Capitalization162.81M
REGENXBIO
Price$8.96
Change-$0.17 (-1.86%)
Volume$467.43K
Capitalization451.48M
PBYI vs RGNX Comparison Chart in %
Loading...
PBYI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PBYI vs. RGNX commentary
Jul 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PBYI is a StrongBuy and RGNX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 27, 2025
Stock price -- (PBYI: $3.28 vs. RGNX: $8.96)
Brand notoriety: PBYI and RGNX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PBYI: 88% vs. RGNX: 54%
Market capitalization -- PBYI: $162.81M vs. RGNX: $451.48M
PBYI [@Biotechnology] is valued at $162.81M. RGNX’s [@Biotechnology] market capitalization is $451.48M. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PBYI’s FA Score shows that 1 FA rating(s) are green whileRGNX’s FA Score has 1 green FA rating(s).

  • PBYI’s FA Score: 1 green, 4 red.
  • RGNX’s FA Score: 1 green, 4 red.
According to our system of comparison, PBYI is a better buy in the long-term than RGNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PBYI’s TA Score shows that 4 TA indicator(s) are bullish while RGNX’s TA Score has 4 bullish TA indicator(s).

  • PBYI’s TA Score: 4 bullish, 5 bearish.
  • RGNX’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, PBYI is a better buy in the short-term than RGNX.

Price Growth

PBYI (@Biotechnology) experienced а -3.53% price change this week, while RGNX (@Biotechnology) price change was +9.80% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.62%. For the same industry, the average monthly price growth was +17.39%, and the average quarterly price growth was +28.36%.

Reported Earning Dates

PBYI is expected to report earnings on Oct 30, 2025.

RGNX is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+7.62% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RGNX($451M) has a higher market cap than PBYI($163M). RGNX YTD gains are higher at: 15.912 vs. PBYI (7.541). PBYI has higher annual earnings (EBITDA): 54.7M vs. RGNX (-122.44M). RGNX has more cash in the bank: 268M vs. PBYI (93.2M). PBYI has less debt than RGNX: PBYI (61.7M) vs RGNX (79.8M). PBYI has higher revenues than RGNX: PBYI (233M) vs RGNX (157M).
PBYIRGNXPBYI / RGNX
Capitalization163M451M36%
EBITDA54.7M-122.44M-45%
Gain YTD7.54115.91247%
P/E Ratio4.21N/A-
Revenue233M157M148%
Total Cash93.2M268M35%
Total Debt61.7M79.8M77%
FUNDAMENTALS RATINGS
PBYI vs RGNX: Fundamental Ratings
PBYI
RGNX
OUTLOOK RATING
1..100
8417
VALUATION
overvalued / fair valued / undervalued
1..100
34
Fair valued
72
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
1996
PRICE GROWTH RATING
1..100
5659
P/E GROWTH RATING
1..100
9723
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PBYI's Valuation (34) in the Biotechnology industry is somewhat better than the same rating for RGNX (72). This means that PBYI’s stock grew somewhat faster than RGNX’s over the last 12 months.

PBYI's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as RGNX (100). This means that PBYI’s stock grew similarly to RGNX’s over the last 12 months.

PBYI's SMR Rating (19) in the Biotechnology industry is significantly better than the same rating for RGNX (96). This means that PBYI’s stock grew significantly faster than RGNX’s over the last 12 months.

PBYI's Price Growth Rating (56) in the Biotechnology industry is in the same range as RGNX (59). This means that PBYI’s stock grew similarly to RGNX’s over the last 12 months.

RGNX's P/E Growth Rating (23) in the Biotechnology industry is significantly better than the same rating for PBYI (97). This means that RGNX’s stock grew significantly faster than PBYI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PBYIRGNX
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
73%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 5 days ago
84%
Bullish Trend 3 days ago
76%
Declines
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 16 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
85%
Aroon
ODDS (%)
Bullish Trend 5 days ago
82%
Bearish Trend 2 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
PBYI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
JUMSY38.656.60
+20.59%
Jumbo SA
AHCHF2.89N/A
N/A
Anhui Conch Cement Co., Ltd.
HSTI1.35N/A
N/A
High Sierra Technologies Inc.
LNCLF0.12N/A
N/A
Lincoln Gold Mng Inc.
ELLRY2.65N/A
N/A
Elringklinger Ag